Feasibility and advantage of adding (131)I-MIBG to (90)Y-DOTATOC for treatment of patients with advanced stage neuroendocrine tumors

BACKGROUND: Peptide receptor radionuclide therapy (PRRT) is an effective form of treatment for patients with metastatic neuroendocrine tumors (NETs). However, delivering sufficient radiation dose to the tumor to result in a high percentage of long-term tumor remissions remains challenging because of...

Descripción completa

Detalles Bibliográficos
Autores principales: Bushnell, David L, Madsen, Mark T, O’cdorisio, Thomas, Menda, Yusuf, Muzahir, Saima, Ryan, Randi, O’dorisio, M Sue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4452658/
https://www.ncbi.nlm.nih.gov/pubmed/26116109
http://dx.doi.org/10.1186/s13550-014-0038-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4452658/
https://www.ncbi.nlm.nih.gov/pubmed/26116109
http://dx.doi.org/10.1186/s13550-014-0038-2

Ejemplares similares